Ohio State University Comprehensive Cancer Center: Lymphoma trials

The registry lists 14 Lymphoma studies with Ohio State University Comprehensive Cancer Center as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 5Phase 2 8No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 2Results posted
• Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT03583424Phase 1/2Results posted
• Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT01812005Phase 2Results posted
• A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT01460940Phase 2Results posted
• Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk LymphomaCompletedNCT00569309Not applicableResults posted
• Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk LymphomaCompletedNCT00561418Phase 1Results posted
• Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaCompletedNCT00201877Phase 2Results posted
• Fatigue Reduction Diet in Lymphoma SurvivorsCompletedNCT05327725Not applicable
• Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedNCT02512497Phase 1
• Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)CompletedNCT01212380Phase 1
• Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell LymphomaWithdrawnNCT00983944Phase 2
• CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell LymphomasCompletedNCT00323323Phase 1
• A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's LymphomaCompletedNCT00201669Phase 2
• Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00143065Phase 2